Trial Profile
A phase IIb trial of emricasan in patients with alcoholic cirrhosis and severe portal hypertension
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2021
Price :
$35
*
At a glance
- Drugs Emricasan (Primary)
- Indications Liver cirrhosis; Portal hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ENCORE-AC
- Sponsors Conatus Pharmaceuticals; Histogen
- 19 Nov 2015 New trial record